Logo

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Share this

Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome

Shots:

  • Ovid to receive $196M as up front and an additional $660M as development- regulatory and sales milestones along with royalties and up to 20% on sales of soticlestat. The agreement is expected to close by end of March 2021
  • Takeda to get all global rights to soticlestat and will be responsible for further WW development and commercialization and Ovid will no longer have any financial obligation to Takeda
  • In Aug 2020- the company reported results of P-II ELEKTRA study that showed a reduction in seizure frequency in children with DS and LGS. Takeda plans to initiate a P-III study in children and adults with the same indication in Q2’21

 ­ Ref: Takeda | Image:Takeda

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions